Remus Pharmaceuticals Limited Stock

Equities

REMUS

INE0O5T01011

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:53 2024-05-31 am EDT 5-day change 1st Jan Change
7,431 INR +3.19% Intraday chart for Remus Pharmaceuticals Limited -2.43% -2.91%
Sales 2022 247M 2.96M Sales 2023 451M 5.41M Capitalization 10.94B 131M
Net income 2022 33M 396K Net income 2023 85M 1.02M EV / Sales 2022 * -
Net cash position 2022 * - 0 Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 38
Yield 2022 *
-
Yield 2023 *
-
Free-Float 35.76%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.19%
1 week-2.43%
1 month+0.84%
3 months+28.12%
6 months+31.70%
Current year-2.91%
More quotes
1 week
6 850.00
Extreme 6850
7 715.00
1 month
6 850.00
Extreme 6850
8 699.00
Current year
4 800.00
Extreme 4800
8 747.00
1 year
2 125.00
Extreme 2125
8 747.00
3 years
1 711.25
Extreme 1711.25
8 747.00
5 years
1 711.25
Extreme 1711.25
8 747.00
10 years
1 711.25
Extreme 1711.25
8 747.00
More quotes
Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredient (API). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, tablet. The therapeutic areas it works include oncology, cardiovascular, anti-diabetic, immune suppressants, anti-biotic, antibacterial, dermatology, central nervous system, and others. Its oncology products include Sorafenib Tablets, Enzalutamide Capsules, Lenalidomide Capsule, and others. Its cardiovascular products include Rivaroxaban Tablets, Ticagrelor Tablets, and others.
More about the company